Table 2.
Number of patients evaluable for response, duration of treatment and survival endpoints
| Trametinib/HCQ (n = 19) |
Trametinib/ Palbociclib (n = 15) |
||
|---|---|---|---|
| Evaluable for response | 13 | 9 | |
| PR | 0 | 1 | |
| PD | 13 | 8 | |
| Not evaluable for response: reason for treatment discontinuation | 6 | 6 | |
| Death before staging | 1 | 1 | |
| Patient request | 2 | 0 | |
| Clinical deterioration | 3 | 0 | |
| Toxicity | 0 | 3 | |
| Lost to follow-up | 0 | 2 | |
| Evaluable for duration of treatment | 16 | 13 | |
| Not evaluable | 3 | 2 | |
| Evaluable for PFS | 17 | 11 | |
| Not evaluable | 2 | 4 | |
| Evaluable for OS | 15 | 6 | |
| Not evaluable | 4 | 9 | |